Rousselot, Darling Ingredients’ health brand, and the global leader of collagen-based solutions1, announces that the European Patent Office (EPO) has granted the company’s patent application for its SiMoGel™ solution – a gelatin-based solution for functional gummies.
Launched in 2018, SiMoGel enables the production of nutraceutical gummies using a starch-free process – providing the hygienic conditions needed for supplements. The gelatin-based solution not only helps optimize the production process of nutraceutical gummies, but also enables producers to bring tasty, innovative and competitive delivery forms to the market.
“We’re delighted to have achieved this important step in protecting our innovative SiMoGel solution,” says Randall C. Stuewe, Chairman and Chief Executive Officer at Darling Ingredients. “The patent grant by the EPO strengthens our current patent portfolio and confirms that we are delivering truly innovative solutions to the market. In securing this patent, we are able to offer our customers even more opportunities for secure product development, allowing them to tap into the growing nutraceutical gummy market.”
Over the past few years, nutraceutical gummies have proven to be a popular delivery form achieving a CAGR of 37.3% from 2016 to 20202. As the market continues to expand, so too do the opportunities. To further improve gummies as a delivery form, Rousselot recently launched a new SiMoGel-based process solution, which enables the production of center-filled nutraceutical gummies – also known as gummy caps. This unique concept combines the benefits of soft gels and gummies in a single delivery form – making it the first of its kind to be launched on the nutraceutical and pharmaceutical markets.
Marit van der Heijden, Global Marketing & Project Manager at Rousselot adds, “We are committed to using gelatin as the preferred excipient in this application, as we believe its many functional benefits and natural origins bring endless possibilities for consumers to enjoy their daily vitamins, and even medicines.